Area of research
Oncology · Hematology
Research interest
Research focused on Hematopoietic stem cell transplantation and Chimeric antigen receptor, with related work in Immune system, Lymphoma, Immune dysregulation. Notable publications include 'Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era', 'Clinical performance of metagenomic next-generation sequencing for diagnosis of invasive fungal disease after hematopoietic cell transplant', and 'Immune dysregulation and potential targeted therapy in myelodysplastic syndrome'.
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia
Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial
Clinical performance of metagenomic next-generation sequencing for diagnosis of invasive fungal disease after hematopoietic cell transplant
Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy
Infections associated with <scp>CAR</scp> ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy
Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes
Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference
The outcome and predictive model of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia from the Chinese Blood and Marrow Transplant Registry Group
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study
Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial
A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification
Efficient 3D imaging and pathological analysis of the human lymphoma tumor microenvironment using light-sheet immunofluorescence microscopy
High Serum ST2 Level Predicts Progression and Poor Prognosis of <i> <i>De</i> <i>novo</i> </i>myelodysplastic Syndrome
PB2589: EFFICACY AND SAFETY OF ABCD IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS WITH HEMATOLOGIC DISEASES
High Expression of Plasma IL-1β Levels and Transition of Regulatory T-Cell Subsets Correlate with Disease Progression in Myelodysplastic Syndrome
Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial
Yf-H-2015005, a New CXCR4 Antagonist, in the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma: A Randomized-Controlled Phase 3 Study